Aldeyra Therapeutics, Inc. (ALDX) is a publicly traded Healthcare sector company. As of May 21, 2026, ALDX trades at $1.52 with a market cap of $96.51M and a P/E ratio of -2.76. ALDX moved +0.00% today. Year to date, ALDX is -63.44%; over the trailing twelve months it is -34.32%. Its 52-week range spans $1.07 to $7.20. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces ALDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aldeyra Therapeutics Shares Plunge 71% After Third FDA CRL on Reproxalap NDA: Aldeyra Therapeutics shares plunged 71% after the FDA issued a third complete response letter for reproxalap’s NDA for dry eye disease, citing inconsistent efficacy data and lack of substantial evidence. The company plans to request a Type A meeting within 30 days and has $70 million cash runway into 2028.
| Metric | Value |
|---|---|
| Price | $1.52 |
| Market Cap | $96.51M |
| P/E Ratio | -2.76 |
| EPS | $-0.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.20 |
| 52-Week Low | $1.07 |
| Volume | 22.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-33.85M |
| Gross Margin | 0.00% |
2 analysts cover ALDX: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.